Cevimeline
 | |
 | |
| Names | |
|---|---|
| Pronunciation | se vim' e leen[1] |
| Trade names | Evoxac |
| |
| Clinical data | |
| Drug class | Muscarinic agonist[1] |
| Main uses | Dry mouth[1] |
| Side effects | Increased sweating, runny nose, nausea, diarrhea, headaches, dizziness, visual disturbances, tiredness[1] |
| Pregnancy category |
|
| Routes of use | By mouth (capsules) |
| External links | |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608025 |
| Legal | |
| Legal status |
|
| Pharmacokinetics | |
| Protein binding | <20% |
| Chemical and physical data | |
| Formula | C10H17NOS |
| Molar mass | 199.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cevimeline, sold under the brand nameEvoxac, is a medication used to treatdry mouth due toSjögren's syndrome orradiation therapy.[1] It is similar topilocarpine.[2] It is taken by mouth.[1]
Side effects are usually mild and may include increased sweating, runny nose, nausea, diarrhea, headaches, dizziness, visual disturbances, and tiredness.[1] Safety in pregnancy is unclear.[2] It is amuscarinic agonist, which results in increased saliva production.[1]
Cevimeline was approved for medical use in the United States in 2000.[2] It is available as ageneric medication.[3] In the United States a month of medication costs about 52 USD as of 2021.[3]
Medical use
Dosage
The typical dose is 30 mg three times daily.[1]
Side effects
Known side effects includenausea,vomiting,diarrhea, excessivesweating,rash,headache,runny nose,cough,drowsiness,hot flashes,blurred vision, anddifficulty sleeping.[4]
Contraindications includeasthma andangle closure glaucoma.[citation needed]
Mechanism of action
By activating the M3 receptors of theparasympathetic nervous system, cevimeline stimulates secretion by thesalivary glands, thereby alleviating dry mouth.
See also
- Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
- Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect
References
- ↑1.01.11.21.31.41.51.61.71.8"Cevimeline".LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012.Archived from the original on 6 May 2021. Retrieved3 January 2022.
- ↑2.02.12.2"Cevimeline Monograph for Professionals".Drugs.com.Archived from the original on 28 January 2021. Retrieved3 January 2022.Cite error: Invalid
<ref>tag; name "AHFS2022" defined multiple times with different content - ↑3.03.1"Cevimeline Prices, Coupons & Savings Tips - GoodRx".GoodRx.Archived from the original on 26 September 2016. Retrieved3 January 2022.
- ↑[1]Archived 2017-09-30 at theWayback Machine MedicineNet: Cevimeline. Accessed 10/12/2007
External links
| Identifiers: |
|---|
- Pages using duplicate arguments in template calls
- Pages with reference errors
- Webarchive template wayback links
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All articles with unsourced statements
- Articles with unsourced statements from December 2010
- Articles with invalid date parameter in template
- Articles with changed EBI identifier
- Muscarinic agonists
- Oxathiolanes
- Quinuclidines
- Spiro compounds
- Daiichi Sankyo
- RTT